ERLOTINIB ACTAVIS 150mg tablets medication leaflet

L01EB02 erlotinib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

Erlotinib is a medication used in the treatment of certain types of lung cancer and advanced pancreatic cancer. It works by blocking a protein involved in the growth and multiplication of cancer cells, thus helping to slow disease progression.

Erlotinib is administered orally as tablets, once daily, according to the oncologist's instructions. The dose may be adjusted depending on the patient's response to treatment and any side effects.

Side effects may include skin rashes, diarrhea, nausea, fatigue, or, rarely, liver dysfunction and severe allergic reactions. Medical monitoring is necessary throughout the treatment.

Erlotinib is an effective option for patients with advanced lung or pancreatic cancer, offering the chance to prolong survival and improve quality of life.

General data about ERLOTINIB ACTAVIS 150mg

Substance: erlotinib

Date of last drug list: 01-08-2019

Commercial code: W65986001

Concentration: 150mg

Pharmaceutical form: tablets

Quantity: 30

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: S.C. SINDAN-PHARMA S.R.L. - ROMANIA

Holder: ACTAVIS GROUP PTC EHF. - ISLANDA

Number: 11701/2019/01

Shelf life: 30 months

Concentrations available for erlotinib

100mg, 150mg, 25mg, 50mg

Other substances similar to erlotinib